CR Group LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
CR Group LP
CRD #132967
SEC #801-63545
CIK #0001702352, 0001747755
AUM 2,207.6 M (2026-03-31)
Employees 21 (43% Investors, 0% Brokers)
Fees
Minimum
Phone713-209-7350
Address1000 Main Street, Suite 2500
Houston, TX 77002-6340
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
4.03.22.41.60.80.02002201020182027
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
Item 5 – Fees and Compensation

CRG generally receives an annual management fee (the “Management Fee”), as described in
the Client’s respective Advisory Agreements, based upon (a) during the applicable Client’s
investment period, either (1) total investor commitments or (2) total invested capital or the
fair value of managed assets, and (b) thereafter, total invested capital or the fair value of
managed assets, as such terms are defined in the Client’s operating agreement (the “Operating
Agreement”). Under the terms of each Advisory Agreement, the Management Fee is generally
payable quarterly in advance, prorated for the actual number of days if less than three months;
in such a case, the Adviser will return the unearned portion to the Fund.

In addition, CRG may be entitled to receive carried interest or a performance fee (an “Incentive
Fee”), as described in the respective Client’s Operating Agreement and Advisory Agreement.
CRG may negotiate a specific fee arrangement with a particular investor pursuant to a side
letter or other account agreement.

CRG or its affiliates additionally may receive fees from the Funds for additional services
provided to the Funds or their underlying investments not covered by the client’s management
fee (“Related Services”). Any such amounts received for Related Services will generally reduce
management fees paid to the Adviser.

All Clients will incur expenses in connection with custodial or brokerage services discussed in
Item 12. In addition, Clients bear their own operating costs and expenses relating to their
organization and operations, which may include, but are not limited to expenses incurred in
identifying, assessing, acquiring, negotiating, structuring, and disposing of investment
opportunities, including any financing, legal, accounting, management and consulting fees
whether or not a Client actually invests in the specific investment opportunity or not;
administrative expenses associated with an annual audit, financial and tax returns and tax
reporting to a Client’s investors; registration and other investment costs; interest and fees
associated with any permitted borrowings; costs of any litigation, D&O insurance and other
types of insurance, indemnification or extraordinary expense or liability; meetings of Client
investors; fees and disbursements to attorneys, consultants, accountants, fund administrators,
service providers and any other professionals relating to Client matters.

Allocation of Expenses

CRG frequently will be required to decide how certain costs and expenses are to be allocated
to one or more Funds, and to other Clients of the Adviser. Certain expenses may be suitable for
only a particular Fund or Funds or another participating Client and borne only by such vehicles,
or, as is more often the case, expenses may be allocated pro rata among each participating
Client in accordance with expense allocation policies and procedures developed by the Adviser,
as may from time to time be amended or revised by the Adviser in its sole discretion. Generally,
expenses are expected to be allocated based on contributions to the applicable Portfolio
Investment. However, the Adviser may determine in its sole discretion that allocation in a
different manner would be fair and equitable in certain cases that may result in one or more
Funds bearing a higher share of expenses. For example, the Adviser may determine to use a
different allocation of expense where the applicable expense has been incurred based on some
factor other than asset or investment size (such as the number of investors in each parallel
fund) or where the expense would be incurred by one or more parallel funds regardless of the
existence of, or participation in the benefits of such expense by, another parallel fund or client.
Notwithstanding the foregoing, the portion of an expense allocated to a Fund for a particular
service may not reflect the relative benefit derived by the Fund from that service in any
particular instance. CRG may make allocation decisions that result in a general partner or the
Adviser bearing a smaller portion of expenses and/or receiving greater amounts of
management fees than would have been the case had expenses been allocated pro rata.
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
Item 7 – Types of Clients

The Adviser provides investment management services to several Funds. Investors in the
Funds may include certain qualified individuals, public pensions, corporate pension and profit-
sharing plans, charitable institutions, foundations, endowments, municipalities, private
investment funds, trust programs, insurance companies, sovereign funds, foreign funds and
other U.S. and international institutions. CRG has also provided investment management
services to separately managed accounts of investors with similar profiles as those who have
invested in the Funds.
Type Form D Funds Date Sold AUM
PE CRG Partners V Cayman Parallel Fund C LP [2023-03-30] 526.5 M 371.0 M
Offered $2,000,000,000 · Filed 2023-09-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,473,487,000 · Duration One year or less · Commission $77,346 · Revenue Decline to Disclose
PE CRG Partners V Cayman Parallel Fund LP [2023-03-30] 526.5 M 77.4 M
Offered $2,000,000,000 · Filed 2023-09-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,473,487,000 · Duration One year or less · Commission $77,346 · Revenue Decline to Disclose
PE CRG Partners V Delaware Parallel Fund LP [2023-03-30] 526.5 M 95.1 M
Offered $2,000,000,000 · Filed 2023-09-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,473,487,000 · Duration One year or less · Revenue Decline to Disclose
PE CRG Partners IV - Cayman Levered LP [2019-03-29] 166.1 M
Filed 2019-10-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE CRG Partners IV LP [2019-03-29] 229.8 M 165.2 M
Filed 2019-10-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE CRG Partners IV - Parallel Fund C Cayman LP [2019-03-29] 600.0 M 338.3 M
Filed 2019-10-11 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE CRG Partners III Cayman LP [2016-03-29] 89.0 M 61.9 M
Filed 2016-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $399,000 · Revenue Decline to Disclose
PE CRG Partners III LP [2016-03-29] 41.5 M 26.5 M
Filed 2016-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $124,500 · Revenue Decline to Disclose
PE CRG Partners III - Parallel Fund A LP [2016-03-29] 27.3 M 18.9 M
Filed 2016-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $409,500 · Revenue Decline to Disclose
PE CRG Partners III - Parallel Fund B Cayman LP 2016-03-29 55.0 M
View All
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 10 2.2
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 10 2.2
By Discretionary
Discretionary 10 2.2
Non-Discretionary 0 0.0
Total 10 2.2
By Non-United States Persons
Non-United States Persons 1.7
United States Persons 0.5
Total 10 2.2
Form D Directors Role # Filings # Firms 2011 - 2026
Sabrina Foster Director 43 16
Omar Wright Director 88 13
Charles Tate Executive Officer 16 2
Nathan Hukill Executive Officer, Promoter 9 2
Andrei Dorenbaum Executive Officer, Promoter 7 2
Luke Duster Executive Officer, Promoter 6 2
Sebastian Arango Promoter 3 1
Adam Whitehead Promoter 3 1
Meredith Gamble Promoter 3 1
Crg Partners V Cayman GP LP Executive Officer 1 1
View All
EDGAR Form CIK 2011 - 2026
3 [0001702352]
4 [0001702352]
SC 13D [0001702352]
SC 13G [0001702352]
D [0001747755]
Form 13D/13G Filer Form 13D/13G Subject Filed
CR Group LP T2 Biosystems Inc [2024-04-19]
CR Group LP T2 Biosystems Inc [2023-07-13]
CR Group LP Assertio Holdings Inc [2020-05-28]
CR Group LP Tearlab Corp [2020-05-21]
CR Group LP Avinger Inc [2020-02-13]
CR Group LP Viveve Medical Inc [2020-02-13]
Capital Royalty LP Strongbridge Biopharma PLC [2018-12-28]
Capital Royalty LP Valeritas Holdings Inc [2017-04-07]
Firm Profile (Form ADV)
Discretionary AUM$1.0B
ServesInstitutional
Fund TypesPrivate Equity
Form 3/4/5 Subject 2011 - 2026
CRG Partners III - Parallel Fund B Cayman LP
CRG Partners III Cayman Lev AIV I LP
CRG Partners III - Parallel Fund A LP
CRG Partners III LP
CRG Partners III Cayman Unlev AIV I LP
CR Group LP
T2 Biosystems Inc
Avinger Inc
Loan Security Holdings I LLC
Assertio Holdings Inc
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
T2 Biosystems Inc TTOO
Common Stock
2024-05-09 Conversion 108,752
T2 Biosystems Inc TTOO
Series A Preferred Stock · derivative
2024-05-09 Conversion 17,160.48 $0.00
T2 Biosystems Inc TTOO
Series B Preferred Stock · derivative
2024-05-09 Conversion 10,875.25 $0.00
T2 Biosystems Inc TTOO
Common Stock
2024-05-09 Conversion 1,716,048
T2 Biosystems Inc TTOO
Common Stock
2024-05-03 Grant 403,608
T2 Biosystems Inc TTOO
Common Stock
2024-05-03 Grant 1,565,445
T2 Biosystems Inc TTOO
Common Stock
2024-05-03 Grant 129,629
T2 Biosystems Inc TTOO
Common Stock
2024-05-03 Grant 648,139
T2 Biosystems Inc TTOO
Common Stock
2024-05-03 Grant 2,001,514
T2 Biosystems Inc TTOO
Common Stock
2024-04-12 Grant 424,716
T2 Biosystems Inc TTOO
Series A Convertible Preferred Stock · derivative
2024-04-12 Grant 17,160.48 $0.00
T2 Biosystems Inc TTOO
Common Stock
2024-04-12 Grant 1,647,315
T2 Biosystems Inc TTOO
Common Stock
2024-04-12 Grant 682,036
T2 Biosystems Inc TTOO
Common Stock
2024-04-12 Grant 390,142
T2 Biosystems Inc TTOO
Common Stock
2024-04-12 Grant 136,409
T2 Biosystems Inc TTOO
Series B Preferred Stock · derivative
2024-02-14 Conversion 33,594.71 $0.00
T2 Biosystems Inc TTOO
Common Stock
2024-02-14 Conversion 335,947
T2 Biosystems Inc TTOO
Series B Preferred Stock · derivative
2024-02-14 Conversion 48,827.30 $0.00
T2 Biosystems Inc TTOO
Common Stock
2024-02-14 Conversion 488,273
T2 Biosystems Inc TTOO
Common Stock
2023-09-28 Sell 2,858,980 $0.16 457,437
showing 20 of 98 most recent transactions
Comparable Firms State AUM
Hidden Harbor Capital Management LP
FL 2,235.2 M
EIV Capital LLC
TX 2,232.2 M
CCMP Capital Advisors LP
NY 2,229.0 M
Two Sigma Ventures LP
NY 2,226.1 M
Longrange Capital LP
CT 2,219.6 M
Further Global Capital Management LP
NY 2,215.6 M
Kosmos Management LLC
WA 2,205.9 M
Pacific Lake Partners LLC
MA 2,179.9 M
CAI Manager LP
CA 2,177.7 M
Ascend Capital Partners Manager LP
NY 2,176.3 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com